Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2013 Oct;17(Suppl 1):S139-41.
doi: 10.4103/2230-8210.119534.

Resistant prolactinoma: Is it monoclonal or polyclonal?

K V S Hari Kumar  1 , Pitambar Prusty
Affiliations
Case Reports

Resistant prolactinoma: Is it monoclonal or polyclonal?

K V S Hari Kumar et al. Indian J Endocrinol Metab. 2013 Oct.

Abstract

Prolactinomas are solitary benign neoplasms and resistance to dopamine agonists occur in a small percentage of prolactinomas. Multiple pituitary adenomas are reported in less than 1% of pituitary adenomas and rarely result in resistant prolactinoma. We recently encountered an interesting patient of hyperprolactinemia with multiple pituitary microadenomas. Dopamine agonist use resulted in prolactin normalization and subsequent pregnancy resulted in drug withdrawal. Repeat evaluation after delivery showed a macroprolactinoma and dopamine agonist therapy resulted in biochemical cure without reduction in tumor size. We report the case for its presentation with multiple microadenomas progressing to macroprolactinoma suggesting polyclonal in origin.

Keywords: Multiple pituitary adenoma; polyclonal; resistant prolactinoma.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared

Figures

Figure 1
Figure 1
MRI showing (a) multiple microadenomas and (b) with dynamic mean curve analysis
Figure 2
Figure 2
MRI showing pituitary macroadenoma
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Molitch ME. Dopamine resistance of prolactinomas. Pituitary. 2003;6:19–27. - PubMed
    1. Jastania RA, Alsaad KO, Al-Shraim M, Kovacs K, Asa SL. Double adenomas of the pituitary: Transcription factors Pit-1, Tpit, and SF-1 identify cytogenesis and differentiation. Endocr Pathol. 2005;16:187–94. - PubMed
    1. Asa SL, Ezzat S. Molecular basis of pituitary development and cytogenesis. In: Kontogeorgos G, Kovacs K, editors. Molecular pathology of the pituitary. Vol. 32. Basel: Karger; 2004. pp. 1–19. - PubMed
    1. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev. 2006;27:485–534. - PubMed
    1. Herman V, Drazin NZ, Gonsky R, Melmed S. Molecular screening of pituitary adenomas for gene mutations and rearrangements. J Clin Endocrinol Metab. 1993;77:50–5. - PubMed

Publication types